Communication of the meeting of Transparency Council No. 49/2025 on 17 November 2025 with resolutions

We invite you to read minutes of the meeting of Transparency Council No. 49/2025 on 17 November 2025 during which the following resolutions were adopted:

1. At its meeting on 17 November 2025, the Transparency Council adopted position No. 168/2025 on the legitimacy of classifying the healthcare service “Procedure for programming an intracranial brain neurostimulator and monitoring patients with an implanted intracranial brain neurostimulator” as a guaranteed service
2. At its meeting on 17 November 2025, the Transparency Council adopted opinion No. 201/2025 on the introduction of the medicinal product Hemlibra (emicizumab) into the health policy program “National Program for the Treatment of Patients with Hemophilia and Related Bleeding Disorders for 2024-2028”
3. At its meeting on 17 November 2025, the Transparency Council adopted opinion No. 202/2025 on the reimbursement of medicines containing the active substance anakinra for indications, dosages, or methods of administration other than those specified in the Summary of Product Characteristics
4. At its meeting on 17 November 2025, the Transparency Council adopted opinion No. 203/2025 on the reimbursement of medicines containing the active substance chloroquine in indications for use or dosage, or method of administration other than those specified in the Summary of Product Characteristics
5. At its meeting on 17 November 2025, the Transparency Council adopted opinion No. 204/2025 on the reimbursement of medicines containing the active substance metformine for indications, dosages, or methods of administration other than those specified in the Summary of Product Characteristics
6. At its meeting on 17 November 2025, the Transparency Council adopted opinion No. 205/2025 on the reimbursement of medicines containing the active substance venlafaxine for indications, dosages, or methods of administration other than those specified in the Summary of Product Characteristics
7. At its meeting on 17 November 2025, the Transparency Council adopted opinion No. 206/2025 on the reimbursement of medicinal products containing the active substance stiripentolum for indications, dosages, or methods of administration other than those specified in the Summary of Product Characteristics
8. At its meeting on 17 November 2025, the Transparency Council adopted opinion No. 207/2025 on the reimbursement of medicines containing the active substance abiraterone acetate for indications, dosages, or methods of administration other than those specified in the Summary of Product Characteristics

Transparency Council meeting protocol >>